Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics.
- Author:
Kai-Long YUAN
1
;
Xian-Zhe SHI
;
Xin LU
;
Peng GAO
;
Guo-Wang XU
Author Information
- Publication Type:Journal Article
- MeSH: Albuminuria; urine; Biomarkers; blood; chemistry; urine; Chromatography, Gas; methods; Creatinine; blood; Deoxyguanosine; analogs & derivatives; urine; Diabetes Mellitus; drug therapy; Diabetes Mellitus, Type 2; drug therapy; Drug Monitoring; Humans; Hypoglycemic Agents; therapeutic use; Inositol; chemistry; Losartan; therapeutic use; Metabolome; drug effects; Sorbitol; chemistry
- From: Acta Academiae Medicinae Sinicae 2007;29(6):719-724
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo assess the therapeutic effect of losartan on type 2 diabetes mellitus (DM2) with gas chromatography (GC)-based metabonomics.
METHODSDM2 patients were dosed with losartan (100 mg/d) and urines were collected at week 8 and 12. The biochemical criteria (blood pressure, urinary albumen, urinary 8-hydroxy-2'-deoxyguanosine and blood creatinine) were analyzed. Urine samples were derivatived and analyzed by GC. Multivariate metabonomics analysis was performed after peak alignment.
RESULTSAfter 8-12 weeks, losartan showed little curative effect and no remarked changes of biochemical criteria were observed. However, metabonomics analysis revealed that some biomarkers such as glucitol and inositol changed.
CONCLUSIONGC-based metabonomics analysis enables the rapid identification of metabolic differences and provides information concerning therapeutic effect of losartan.
